Which of the following is given to treat thrombocytopenia secondary to anti cancer therapy and is known to stimulate progressive megakaryocytes
**Core Concept:** Thrombocytopenia refers to a decrease in platelet count, which can be caused by various factors including anti-cancer therapy. Thrombopoietin (TPO) is a hormone that promotes platelet production through stimulation of megakaryocytes, which are primary cells responsible for platelet production in the bone marrow. Progressive megakaryocytes are more sensitive to TPO than non-progressive ones.
**Why the Correct Answer is Right:** Option C, Thrombopoietin (TPO), is the correct answer as it is a hormone that stimulates the production of platelets by promoting the development of progressive megakaryocytes in the bone marrow. TPO increases the sensitivity of megakaryocytes to platelet production, which is beneficial in treating thrombocytopenia secondary to anti-cancer therapy.
**Why Each Wrong Option is Incorrect:**
A. Erythropoietin (EPO): EPO is responsible for erythropoiesis, the production of red blood cells, and is unrelated to platelet production. It is not a suitable option for treating thrombocytopenia.
B. Antithyroid drugs: These medications are used to treat hyperthyroidism and thyroid disorders, not related to thrombocytopenia or platelet production. They are also not a suitable option for treating thrombocytopenia.
D. Cortisol: Cortisol is a steroid hormone associated with the body's stress response and inflammation regulation. It is not involved in platelet production or involved in the treatment of thrombocytopenia.
**Clinical Pearl:** Thrombopoietin (TPO) agonists like romiplostim and eltrombopag are specific medications used for the treatment of thrombocytopenia in patients undergoing chemotherapy. They stimulate the production of progressive megakaryocytes and platelets, ultimately improving thrombocytopenia.